MedTrace Logo

Impact of Sleep Disorders on Innate Immunity in COVID-19 Patients

NCT06341374 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2024-04-02

No results posted yet for this study

Summary

Sleep is an important modulator of the immune response, whereby sleep disturbances (ie, poor sleep quality, insufficient sleep and/or primary sleep disorder, obstructive sleep apnea (OSA)) contribute to inflammatory disease risk and dysregulation of immune response in front of infectious agents.

The objective of this study is to evaluate the impact of undiagnosed and non-treated sleep disorders on innate immunity in a cohort of COVID-19 patients and the role of trained immunity induced by influenza vaccination in the innate immune response.

Conditions

  • Apnea, Obstructive Sleep
  • SARS CoV 2 Infection

Interventions

BIOLOGICAL

Influvac Tetra

All participants will take influenza vaccine (Influvac Tetra, Abbott Biologicals, IL, USA) and the trained immune response will be evaluated.

Sponsors & Collaborators

  • Parc Taulí Hospital Universitari

    lead OTHER

Principal Investigators

  • Maria Jose M Masdeu, Medicine · Hospital Universitari Parc Tauli, Sabadell

  • Andrea F Grau, Medicine · Hospital Universitari Parc Tauli, Sabadell

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-11-06
Primary Completion
2024-03-30
Completion
2024-09-30

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06341374 on ClinicalTrials.gov